A subgroup of patients with NSCLC having specific mutations in the tyrosine kinase domain of EGFR gene, which correlates with favorable clinical responsiveness to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib, erlotinib, and afatinib therapy, has been noted [2–4]. Here, EGFR is linked to non-small cell lung carcinoma.